, , ,









Great little Company, looking like it is through its growing pain stage, onwards and upwards

********************************************************************

Scancell Hlds
Patent Approval
RNS Number : 0217Z
Scancell Holdings Plc
09 March 2012


9 March 2012





Scancell Holdings plc

("Scancell" or "the Company")

ImmunoBody® Patent Approved in US



Scancell Holdings plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that its protein ImmunoBody® vaccine patent has been approved in the United States. The patent, which has already been approved in Europe and Australia, will further strengthen Scancell's IP position around its proprietary ImmunoBody® vaccine platform.



Scancell's lead vaccine, SCIB1 is being developed for the treatment of melanoma and is currently in Phase I clinical trials. It is an innovative DNA vaccine being developed using Scancell's ImmunoBody® technology. Phase 2 trials are due to start in Q2 2012.



Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:



"The USA remains the most important market in which to commercialise our ImmunoBody ® vaccines. The award of this US patent confirms the innovative nature of the ImmunoBody ® platform and provides a sound basis on which to commercialise the technology in the US. Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme forward during 2012

*******************************************************************

Especially......
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:



"The USA remains the most important market in which to commercialise our ImmunoBody ® vaccines. The award of this US patent confirms the innovative nature of the ImmunoBody ® platform and provides a sound basis on which to commercialise the technology in the US. Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme forward during 2012


This is why all the excitement here.

Courtesy of the poster brigadon on LSE.


Make That A Billion Dollars!

After years of developing the melanoma antigens TRP - 2 and gp100 at the National Cancer Institute in Bethesda, Maryland, the United States Department of Health and Human Services (HHS) has entrusted Scancell with their commercial development. These antigens now form key components in the company's lead vaccine to treat melanoma, SCIB1.

The US Public Health Service, a division of HHS is due royalty payments on these antigens from future sales of SCIB1 so, to help realise a speedy return on its investment, the US National Institutes of Health, an agency of the US Department of Health has made the clinical trials data for SCIB1 available on its website, an important port of call for large pharmaceutical companies looking for new drugs and drug development businesses to acquire. [Scancell's board has expressed the intention to seek a 'trade sale' of the business upon completion of Phase II clinical trials of its lead vaccine SCIB1.]

In a recent presentation to analysts and investors Scancell made the point that large pharmaceutical companies were prepared to pay up to a billion dollars for a clinical stage cancer vaccine firm, such as Scancell, which had shown evidence of patient recovery from terminal forms of the disease after treatment with its products. In May 2010 it was revealed that an earlier version of SCIB1, configured at the time to treat bone cancer had indeed appeared to have cured two young patients of a terminal form of this condition.

It is this pedigree of Scancell's curative success, the watertight protection of its patents and the influential backing of the US Department of Health that any potential bidder will be buying into. So even if we were to assume the price being offered for Scancell, was only half of what has been offered in similar circumstances this could still amount to to an offer price of around 162p per share! Whatever the final price, it will certainly amount to many multiples of today's market price. I am therefore maintaining my Strong BUY recommendation for this stock.

I got in last Thursday. Paid a little higher than should've doen but it's going to be peanuts compared to what this nice little earner could return! (imho)

Anyone else in ?

Skyhigh, you'd not be so pleased if you'd invested a year earlier...since then the Board has trashed the sp by a horendus subdivision and placing at 5p to raise sufficient funds so they can continue. As to a bid at 162p - bring it on . . . but one has to wonder why the US DoH entrusted a British Company to develop such a go-er (my words), when the US is full of folks willing to promote small co's start-ups and the like?
Somehow it doesn't ring right, - but am willing to listen.
Sp today abt 7p

However, to pay for their Trials it seems they've granted 7m Options to a US-Medico (DYOR) which can buy oodles of shares at 4.5p until c.2017 as I read it. This must be an anchor to the sp which has fallen massivly from £1 only a short while ago.

Moditope Vaccine Technology Platform

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the development of a new platform technology (ModitopeÔ) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The Directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed.

TRADE SALE STILL ON NEXT YEAR

Scancell (SCLP) has announced its new technology platform will not alter its intention to sell next year.

AIM-quoted cancer vaccine specialist Scancell Holdings (SCLP) has announced its development of a new platform technology - Moditope - that stimulates the production of killer CD4 cells with powerful anti tumour activity. Joint chief executive officer Lindy Durrant commented that this new discovery could have a 'profound effect' on cancer vaccine development in the future.

The new venture follows Scancell's successful ongoing clinical trial of SCIB1, another cancer vaccine, which was developed using the company's groundbreaking ImmunoBody technology platform. This vaccine is currently being developed for the treatment of melanoma and is in Phase 2 clinical trials.

What the company intends to do with its latest discovery is an interesting topic. Fellow chief executive Richard Goodfellow admitted the directors 'have to sit down with the shareholders' to discern what the best strategy is. He added that in no way was this 'chance finding' going to derail the company's intention to look for a buyer late next year.

Plans might include creating a separate company which is purely responsible for raising funds and driving through Moditope to trial. 'It's a nice problem to have' Mr Goodfellow concluded, but reinforced that the company was committed to finding the 'greatest value' for shareholders.

Over the last year Scancell's share price has spiked from a 52 week low of 4.5p to a high of 28.7p. They are currently trading at 25.88p.

Source:

http://www.growthcompany.co.uk/news/2116623/scancell-still-to-sell.thtml

Up another 30% today.

Hmmm....'chance finding'.....Viagra was a chance finding.

Rodders

20 August 2012

Scancell Holdings Plc

('Scancell')


Market Update


The Board of Scancell (AIM:SCLP) have noted the continuous raise in its share price over the last 10 days and in particular following the announcement on 15 August 2012 relating to the Moditope vaccine technology platform.

The Board is actively evaluating its strategic options for the Moditope platform and will be consulting with key shareholders in this regard. As regards SCIB1, the cancer vaccine being developed for the treatment of melanoma and the Company's DNA ImmunoBody(R) vaccine technology upon which it is based, the Board reiterates that its strategy will be to seek a buyer on completion of the Phase I/II clinical trial, which is expected in late 2013.

The Board will update the market in due course.

-ENDS-

Duplicate!

Well done to all in this one

Helium Special Situations Fund Limited from 6.88% to 5.87%.

Scancell Holdings a biopharmaceutical company focused on the cancer therapeutics market, and the third-most popular 'buy' by TD Direct Investing's retail clients this morning. The shares are up 10% as I write these words, with bulletin board traffic -- as opposed to hard news or company statements -- the apparent cause.

That said, the shares are up 750% (yes, you read that right) this year, so investors will need to be confident that enough upside remains. Me?

Well this has had a roller coaster of a day for sure...

Scancell's amazing rise continues - UPDATE
Mon 08 Oct 2012

SCLP - Scancell Holdings

Latest Prices
Name Price %
Scancell Holdings 53.25p +4.41%

FTSE AIM All-Share 702 -0.72%
Pharmaceuticals & Biotechnology 9,833 -0.56%

LONDON (SHARECAST) - Scancell, the developer of therapeutic cancer vaccines, continued its amazing price rise in early morning trade on Monday to become a 10-bagger in only a few months.

It has apparently been propelled by hopes its news technology platform for anti-cancer vaccines, called Moditope, will be able to successfully produce an anti-cancer vaccine that destroys tumours without toxicity.

David Lowery, equity analyst at Faraday Research told Digital Look that the development was “potentially ground-breaking” and that “If the discovery is as big as it sounds the shares are potentially worth several pounds.”

Canny investor David Newton, from the Helium Special Situations fund, has been a long term holder of the company and has a stake of 6.88%.

In mid-morning trade the shares stood at 59.5p, up 16.67% on the day. The share price is now 80% higher over the past month and up a whopping 1,000% over the last year.

Yeah...that good....:-)

Final Results

Highlights during the period:

· In July 2011, Scancell raised £1.58 million, net of expenses, by way of a placing of new shares

· New lung cancer vaccine, SCIB2 - latest anti-tumour results in animal models provide further validation of ImmunoBody® vaccine technology platform and its commercial potential

· In November 2011, received milestone payment from Arana Therapeutics of £2.49 million net of costs

· Completion of recruitment to Phase 1 of the clinical trial for SCIB1 in April 2012

· Profit for the year of £557,058 (2011:loss £1,649,225)

· Cash at year end £3,529,007 (2011: £1,110,630)

Post period highlights:
· On 15 August, 2012 Scancell announced the development of a new platform technology, ModitopeÔ, that stimulates the production of killer CD4 T cells with powerful anti-tumour activity.

Share Nominees Ltd > 9%

SCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that the Gene Therapy Advisory Committee ('GTAC') and the Medicines and Healthcare products Regulatory Agency ('MHRA') Medicines Division have given their approval to dose an extra group of patients with a higher, 8 mg, dose of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma.

The new cohort will recruit up to six more patients and will be recruited in parallel with the patients being recruited into Part 2 of the study. Patients with metastatic tumour present may enter the new cohort so that their tumour response can be assessed, whereas patients who have had their tumours surgically removed may enter Part 2. In addition, Scancell's partner Ichor Medical Systems ('Ichor') has obtained the required parallel approval from the MHRA Devices Division for the use of Ichor's TriGrid™ electroporation delivery device to administer SCIB1 to this additional group of patients."

Scancell is planning to start treating patients with the 8mg dose in the new year.

Update on patient recruitment in clinical trial

Update on patient recruitment in the ongoing SCIB1 clinical trial


Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the recruitment and treatment of the final patient in the second part of its Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. This part of the trial is being conducted in five UK centres in patients with Stage III/IV disease to further assess the safety of treatment and to assess the cellular immune response induced by SCIB1. Patients are being treated with a 4mg dose of SCIB1 on five occasions over a period of 6 months.

In December 2012, Scancell released preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma. Also in December 2012, Scancell announced that the Gene Therapy Advisory Committee ('GTAC') and the Medicines and Healthcare products Regulatory Agency ('MHRA') Medicines Division had given their approval to dose an extra group of patients with a higher, 8 mg, dose of SCIB1. Scancell is planning to start treating patients with the 8mg dose shortly.

Half Yearly Report

Highlights

· Encouraging preliminary results from Part 1 of the Phase 1/2 clinical trial for SCIB1 announced in December 2012

· First evidence that the vaccine is producing an immune response in cancer patients which may also be associated with clinical benefit

· Approval received to dose an extra group of patients with a higher, 8mg, dose of SCIB1

· Recruitment and treatment of the final patient in the second part of its Phase 1/2 clinical trial of SCIB1

ImmunoBody® Patent Approved for Grant in Japan.

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that a patent for its protein ImmunoBody® vaccine technology has been approved for grant in Japan. The patent has already been approved in the US, Europe and Australia.